BIOSYN VAGINAL MICROBICIDE PHASE I TRIALS PLANNED FOR SEPTEMBER
Executive Summary
BIOSYN VAGINAL MICROBICIDE PHASE I TRIALS PLANNED FOR SEPTEMBER, the Philadelphia-based company said July 7. The product, which has been tested in vitro for safety and efficacy in preventing the transmission of AIDS, will also be tested for contraceptive efficacy. The product was designed to combine both contraception and protection against multiple sexually transmitted diseases. The company said it will file an IND "shortly" for the new chemical entity, which it describes only as "a synthetic organic molecule."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth